IPH.PA
Price:
$1.556
Market Cap:
$125.96M
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 ...[Read more]
Industry
Biotechnology
IPO Date
2006-11-01
Stock Exchange
EURONEXT
Ticker
IPH.PA
According to Innate Pharma S.A.’s latest financial reports and current stock price. The company's current PE Ratio is -3.70. This represents a change of -49.49% compared to the average of -7.33 of the last 4 quarters.
The mean historical PE Ratio of Innate Pharma S.A. over the last ten years is 1.49. The current -3.70 PE Ratio has changed -24957.89% with respect to the historical average. Over the past ten years (40 quarters), IPH.PA's PE Ratio was at its highest in in the December 2015 quarter at 357.37. The PE Ratio was at its lowest in in the March 2016 quarter at -101.42.
Average
1.49
Median
-5.70
Minimum
-105.77
Maximum
143.33
Discovering the peaks and valleys of Innate Pharma S.A. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 953.20%
Maximum Annual PE Ratio = 143.33
Minimum Annual Increase = -2746.04%
Minimum Annual PE Ratio = -105.77
Year | PE Ratio | Change |
---|---|---|
2023 | -27.85 | 953.20% |
2022 | -2.64 | -55.81% |
2021 | -5.98 | 54.89% |
2020 | -3.86 | -79.69% |
2019 | -19.02 | -113.27% |
2018 | 143.33 | -2746.04% |
2017 | -5.42 | -108.70% |
2016 | 62.26 | -158.87% |
2015 | -105.77 | 424.49% |
2014 | -20.17 | -69.62% |
The current PE Ratio of Innate Pharma S.A. (IPH.PA) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-12.16
5-year avg
-11.87
10-year avg
1.49
Innate Pharma S.A.’s PE Ratio is less than Genfit S.A. (155.70), greater than Nanobiotix S.A. (-5.35), less than ERYTECH Pharma S.A. (-0.48), less than Cellectis S.A. (-2.09), less than AB Science S.A. (-2.86),
Company | PE Ratio | Market cap |
---|---|---|
155.70 | $221.21M | |
-5.35 | $179.12M | |
-0.48 | $48.66M | |
-2.09 | $127.46M | |
-2.86 | $52.68M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Innate Pharma S.A. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Innate Pharma S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Innate Pharma S.A.'s PE Ratio?
How is the PE Ratio calculated for Innate Pharma S.A. (IPH.PA)?
What is the highest PE Ratio for Innate Pharma S.A. (IPH.PA)?
What is the 3-year average PE Ratio for Innate Pharma S.A. (IPH.PA)?
What is the 5-year average PE Ratio for Innate Pharma S.A. (IPH.PA)?
How does the current PE Ratio for Innate Pharma S.A. (IPH.PA) compare to its historical average?